All Oncology News

Nancy Nixon, MD, discusses the retrospective study of the evolution of biosimilars in oncology, with a focus on trastuzumab and the path toward the integration of biosimilars into cancer care.

The FDA has granted a priority review designation to a supplemental biologics license application for the frontline combination of atezolizumab plus nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.

Recently approved therapy is administered through program at New Jersey’s Only National Cancer Institute-designated Comprehensive Cancer Center.

Results of the phase III CORAIL trial demonstrated that the marine-derived treatment lurbinectedin did not improve progression-free survival compared with pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer.

Rutgers Cancer Institute investigator was awarded a grant to identify new treatment approaches in non–small cell lung cancer.

The FDA has granted a priority review designation to a supplemental new drug application for olaparib tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.

Jeffrey C. Lombardo, PharmD, BCOP, discusses the potential impact that ready-to-use formats for cytotoxic drugs might have in the oncology arena.

The FDA has approved pembrolizumab for the treatment of patients with hepatocellular carcinoma who have previously received sorafenib.

Meagan A. Jacoby, MD, PhD, discusses treatment-free remissions in patients with chronic-phase chronic myeloid leukemia.

Jonathan E. Rosenberg, MD, discusses the extended follow-up of the CheckMate-032 study, as well as the future of immunotherapy in urothelial carcinoma.

Peter E. Clark, MD, discusses the role of surgery in the rapidly evolving treatment paradigm for patients with renal cell carcinoma.

Treatment for cutaneous squamous cell carcinoma (CSCC) took a great leap forward in September 2018 with the PD-1 inhibitor cemiplimab becoming the first agent specifically approved by the FDA for advanced CSCC.

The treatment armamentarium for adjuvant melanoma has expanded rapidly, which has left the treatment challenge of selecting between immunotherapy and targeted therapy without any head-to-head comparative data.

Future development of novel immunotherapy combinations should be based on individual patient characteristics, such as patient-level immune targets and tumor microenvironment.

The FDA has accepted a supplemental new drug application for review for avatrombopag (Doptelet) as a treatment for patients with chronic immune thrombocytopenia who have had an inadequate response to prior treatment.

ASCO and the entire oncology community are deeply saddened by the loss of colleague, friend, ASCO Board of Directors member, and geriatric oncology leader Arti Hurria, MD, FASCO.

Real-world incidences of nausea, thrombocytopenia, and fatigue were markedly lower in patients with platinum-sensitive, recurrent ovarian cancer receiving a starting 200-mg daily dose of niraparib versus those enrolled on the phase III ENGOT-OV6/NOVA trial.

Novel agents and treatment strategies continue to expand the armamentarium in follicular lymphoma, explains John P. Leonard, MD, in a session at the 36th Annual CFS®.

The FDA has granted a fast track designation to selinexor for the treatment of patients with previously treated diffuse large B-cell lymphoma who are ineligible to receive high-dose chemotherapy with stem cell rescue or CAR T-cell therapy.

The high durable response rates seen with CAR T-cell therapies have helped fill a high unmet need for patients with relapsed/refractory diffuse large B-cell lymphoma, with questions remaining on the optimal way to use these agents following the FDA approval of 2 therapies in the past year.

The median overall survival for patients with chronic lymphocytic leukemia has more than tripled since the 1970s, primarily due to an ever-expanding armamentarium of novel agents and earlier diagnosis.

In patients with platinum-sensitive recurrent ovarian cancer, the PARP inhibitor rucaparib as maintenance treatment improved progression-free survival versus placebo, despite the number of chemotherapy regimens.

The FDA has approved elotuzumab for use in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide and a proteasome inhibitor.

Balazs Halmos, MD, discusses the latest developments in the treatment paradigm for patients with squamous cell non–small cell lung cancer.

Low NR2F1 expression in disseminated tumor cells (DTCs) that is found in bone marrow may be indicative of developing metastatic breast cancer, according to results of a study published in Breast Cancer Research.

The VEGF inhibitor tivozanib reduced the risk of disease progression or death by 26% compared with sorafenib in patients with highly refractory advanced or metastatic RCC, according to topline findings from the phase III TIVO-3 trial.

A supplemental biologics license application has been submitted to the FDA for the use of brentuximab vedotin (Adcetris) in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma.

The FDA has granted an approval to pegfilgrastim-cbqv, a pegfilgrastim biosimilar, for patients with cancer receiving myelosuppressive chemotherapy, according to Coherus BioSciences, Inc, the manufacturer of the agent.

The FDA has granted lorlatinib an accelerated approval for the treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinases inhibitors (TKIs).

Claud M. Grigg, Jr, MD, discusses the evolving treatment options in the frontline setting for patients with renal cell carcinoma.